Valuation: Astellas Pharma Inc.

Market Cap 4,025B 25.56B 22.7B 21.23B 19.35B 36.42B 2,461B 36.92B 257B 99.42B 1,253B 95.96B 93.88B P/E 2027 *
10.8x
P/E 2028 * 11.4x
Enterprise Value 3,966B 25.18B 22.37B 20.92B 19.06B 35.89B 2,425B 36.38B 253B 97.96B 1,235B 94.55B 92.5B EV / Sales 2027 *
1.69x
EV / Sales 2028 * 1.62x
Free-Float
98.92%
Yield 2027 *
3.47%
Yield 2028 * 3.6%
1 day+3.20%
1 week-5.30%
Current month-2.34%
1 month-1.57%
3 months+10.62%
6 months-11.00%
Current year+12.31%
1 week 12.5
Extreme 12.5
12.9
1 month 11.9
Extreme 11.9
13.2
Current year 11
Extreme 11
14.19
1 year 8.56
Extreme 8.56
14.19
3 years 7.53
Extreme 7.534
14.19
5 years 7.53
Extreme 7.534
15.62
10 years 7.53
Extreme 7.534
16.7
Manager TitleAgeSince
Chief Executive Officer 64 2023-02-09
Director of Finance/CFO 55 2023-10-31
Compliance Officer - 2025-03-31
Director TitleAgeSince
Chairman 66 2023-02-09
Director/Board Member 64 2019-05-31
Director/Board Member 59 2023-05-31
Change 5-day change 1-year change 3-year change Capi.($)
+3.60%-5.30% - - 26.3B
+0.58%-2.91%+40.15%+113.46% 1,025B
-0.50%-5.23%+38.21%+65.67% 623B
+0.03%-1.77%+9.77%+75.15% 459B
+0.12%-3.61%+60.22%+39.85% 355B
-0.36%-3.83%+21.88%+39.69% 336B
-1.19%-2.85%+11.88%+24.64% 270B
-0.81%-5.39%-4.64%+8.46% 247B
-0.14%-2.21%+36.32%+52.24% 220B
-0.65%-3.18%+32.17%+97.21% 183B
Average -0.05%-1.89%+27.33%+57.37% 413.14B
Weighted average by Cap. -0.19%-2.11%+30.69%+69.18%

Financials

2027 *2028 *
Net sales 2,347B 14.9B 13.23B 12.38B 11.28B 21.23B 1,434B 21.52B 150B 57.96B 731B 55.94B 54.73B 2,189B 13.9B 12.35B 11.55B 10.52B 19.81B 1,338B 20.08B 140B 54.07B 682B 52.19B 51.06B
Net income 367B 2.33B 2.07B 1.93B 1.76B 3.32B 224B 3.36B 23.4B 9.06B 114B 8.74B 8.55B 346B 2.19B 1.95B 1.82B 1.66B 3.13B 211B 3.17B 22.05B 8.54B 108B 8.24B 8.06B
Net Debt -59.18B -376M -334M -312M -284M -535M -36.18B -543M -3.78B -1.46B -18.42B -1.41B -1.38B -481B -3.05B -2.71B -2.53B -2.31B -4.35B -294B -4.41B -30.67B -11.87B -150B -11.46B -11.21B
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
14,099
Date Price Change Volume
26-10-02 €12.50 0.00% 0
26-10-01 €12.50 -2.34% 200
26-09-30 €12.80 +1.59% 0
26-09-29 €12.60 -2.33% 0
26-09-28 €12.90 -2.27% 0
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2,310.50JPY
Average target price
2,529.29JPY
Spread / Average Target
+9.47%

Quarterly revenue - Rate of surprise